#Erlotinib is prescribed for patients with non-small cell lung cancer (NSCLC) whose cancer has spread to other parts of the body and that has certain types of epidermal growth factor receptor (EGFR) mutations. Non-small cell #lungcancer (NSCLC) is the leading cause of cancer-related mortality worldwide. Standard treatment approaches such as chemotherapy, radiotherapy, and surgery have reached a plateau in this disease. Erlotinib is available with OddwayInternational under Indian brands #Erlonat by Natco and #Erlocip by Cipla under the strengths of 100 mg and 150 mg at reasonable prices. To get details about Erlotinib, please contact us at +91-987-333-6444 or send us mail at sales@oddwayinternational.com.
http://bit.ly/1XvjNXm
No comments:
Post a Comment